[1] STINTON LM, SHAFFER EA. Epidemiology of gallbladder disease:Cholelithiasis and cancer[J]. Gut Liver, 2012, 6 (2) :172-187.
|
[2] GLAMBEK I, KVAALE G, ARNESJB, et al. Prevalence of gallstones in a Norwegian population[J]. Scand J Gastroenterol, 1987, 22 (9) :1089-1094.
|
[3] EVERHART JE, KHARE M, HILL M, et al. Prevalence and ethnic differences in gallbladder disease in the United States[J].Gastroenterology, 1999, 117 (3) :632-639.
|
[4] KHUROO MS, MAHAJAN R, ZARGAR SA, et al. Prevalence of biliary tract disease in India:A sonographic study in adult population in Kashmir[J]. Gut, 1989, 30 (2) :201-205.
|
[5] NOMURA H, KASHIWAGI S, HAYASHI J, et al. Prevalence of gallstone disease in a general population of Okinawa, Japan[J]. Am J Epidemiol, 1988, 128 (3) :598-605.
|
[6] PORTINCASA P, MOSCHETTA A, PALASCIANO G. Cholesterol gallstone disease[J]. Lancet, 2006, 368 (9531) :230-239.
|
[7] ABOU-SAIF A, AL-KAWAS FH. Complications of gallstone disease:Mirizzi syndrome, cholecystocholedochal fistula, and gallstone ileus[J]. Am J Gastroenterol, 2002, 97 (2) :249-254.
|
[8] PORTINCASA P, DI CIAULA A, de BARI O, et al. Management of gallstones and its related complications[J]. Expert Rev Gastroenterol Hepatol, 2016, 10 (1) :93-112.
|
[9] BARBARA L, SAMA C, MORSELLI LABATE AM, et al. A population study on the prevalence of gallstone disease:The sirmione study[J]. Hepatology, 1987, 7 (5) :913-917.
|
[10] LEE YC, WU JS, YANG YC, et al. Moderate to severe, but not mild, nonalcoholic fatty liver disease associated with increased risk of gallstone disease[J]. Scand J Gastroenterol, 2014, 49 (8) :1001-1006.
|
[11] HUNG SC, LIAO KF, LAI SW, et al. Risk factors associated with symptomatic cholelithiasis in Taiwan:A populationbased study[J]. BMC Gastroenterol, 2011, 11:111.
|
[12] The epidemiology of gallstone disease in Rome, Italy. Part II.Factors associated with the disease[J]. Hepatology, 1988, 8 (4) :907-913.
|
[13] HALLDESTAM I, KULLMAN E, BORCH K. Incidence of and potential risk factors for gallstone disease in a general population sample[J]. Br J Surg, 2010, 96 (11) :1315-1322.
|
[14] LIN I, YANG YW, WU MF, et al. The association of metabolic syndrome and its factors with gallstone disease[J]. BMC Fam Pract, 2014, 15:138.
|
[15] CHEN CH, HUANG MH, YANG JC, et al. Prevalence and risk factors of gallstone disease in an adult population of Taiwan:An epidemiological survey[J]. J Gastroenterol Hepatol, 2006, 21 (11) :1737-1743.
|
[16] BANIM PJ, LUBEN RN, BULLUCK H, et al. The aetiology of symptomatic gallstones quantification of the effects of obesity, alcohol and serum lipids on risk. Epidemiological and biomarker data from a UK prospective cohort study (EPIC-Norfolk) [J]. Eur J Gastroenterol Hepatol, 2011, 23 (8) :733-740.
|
[17] VLZKE H, BAUMEISTER SE, ALTE D, et al. Independent risk factors for gallstone formation in a region with high cholelithiasis prevalence[J]. Digestion, 2005, 71 (2) :97-105.
|
[18] DAVIDE F, ADA D, SIMONA C, et al. Incidence of gallstone disease in Italy:Results from a multicenter, populationbased Italian study (the MICOL project) [J]. World J Gastroenterol, 2008, 14 (34) :5282-5289.
|
[19] WU SL, HUANG ZR, YANG XC, et al. Prevalence of ideal cardiovascular health and its relationship with the 4-year cardiovascular events in a northern Chinese industrial city[J].Circ Cardiovasc Qual Outcomes, 2012, 5 (4) :487-493.
|
[20] Writing Group of 2010 Chinese Guidelines for the Management of Hypertension. 2010 Chinese guidelines for the management of hypertension[J]. Chin J Cardiol, 2011, 39 (7) :579-616. (in Chinese) 中国高血压防治指南修订委员会.中国高血压防治指南2010[J].中华心血管病杂志, 2011, 39 (7) :579-616.
|
[21] Chinese Diabetes Society. Guidelines for the prevention and control of type 2 diabetes in China (2017 Edition) [J]. Chin J Pract Intern Med, 2018, 38 (4) :292-344. (in Chinese) 中华医学会糖尿病学分会.中国2型糖尿病防治指南 (2017年版) [J].中国实用内科杂志, 2018, 38 (4) :292-344.
|
[22] Joint committee issued Chinese guideline for the management of dyslipidemia. 2016 Chinese guideline for the management of dyslipidemia in adults[J]. Chin Circulation J, 2016, 31 (10) :937-953. (in Chinese) 中国成人血脂异常防治指南修订联合委员会.中国成人血脂异常防治指南 (2016年修订版) [J].中国循环杂志, 2016, 31 (10) :937-953.
|
[23] LIU T, WANG YM, SI TF, et al. Predictive value of cumulative body mass index on new-onset cholelithiasis[J]. Chin J Dig Surg, 2017, 16 (2) :188-194. (in Chinese) 刘通, 王一鸣, 司天福, 等.累积体质量指数对新发胆石症的预测价值[J].中华消化外科杂志, 2017, 16 (2) :188-194.
|
[24] MISCIAGNA G, LEOCI C, GUERRA V, et al. The epidemiology of cholelithiasis in southern Italy[J]. Eur J Gastroenterol Hepatol, 1996, 8 (6) :585-593.
|
[25] JANOWITZ P, WECHSLER JG, KUHN K, et al. The relationship between serum lipids, nucleation time, and biliary lipids in patients with gallstones[J]. Clin Investig, 1992, 70 (5) :430-436.
|
[26] LAMBOU-GIANOUKOS S, HELLER SJ. Lithogenesis and bile metabolism[J]. Surg Clin North Am, 2008, 88 (6) :1175-1194.
|
[27] WINGRAVE SJ, KAY CR. Oral contraceptives and gallbladder disease[J]. Lancet, 1982, 2 (8305) :957-959.
|
[28] ABUESHY SA, MAHFOUZ AA, BADR A, et al. Prevalence and risk factors of gallstone disease in a high altitude Saudi population[J]. East Mediterr Health J, 2007, 13 (4) :794-802.
|